Rejected drug may protect against toxic substance common to Alzheimer's and Parkinson's diseases
Monday, August 13, 2012 - 11:31
in Health & Medicine
The second of two studies on latrepirdine demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep disorders, and other neurodegenerative conditions. Scientists found that latrepiridine, known commercially as Dimebon, reduced the level of at least two neurodegeneration-related proteins in mice.